NF-κB/293/GFP-Luc™ Transcriptional Reporter Cell Line

Monitor NF-κB signaling in vitro and screen for genetic and/or small molecule inhibitors and activators, and more – sort with GFP and quantify with luciferase
  • Study NF-κB signaling in 293 TN cells
  • Perform live cell imaging or FACS (300-fold over background NF-κB-dependent GFP signal)
  • Measure pathway activity with luciferase
  • Compatible with a variety of screening methods including small molecule and RNAi

Products

Catalog Number Description Size Price Quantity Add to Cart
TR860A-1 NF-kB/293/GFP-Luc Transcriptional Reporter Cell Line >2 x 10^6 Cells $3,014.00
- +
Contact Us

Overview

Overview

Monitor NF-κB signaling in Jurkat cells Speed your studies with this pre-built 293 TN-based cell line for monitoring NF-κB signaling in real time. We’ve already integrated an expression cassette that includes NF-κB-responsive transcriptional elements upstream of a minimal CMV promoter (mCMV)-GFP-luciferase cassette. Expression of GFP (up to 300-fold over background) and luciferase only occurs in the presence of active NF-κB signaling, enabling screening for genetic and/or small molecule inhibitors and activators of the NF-κB signaling pathway. Use GFP fluorescence for live cell imaging and FACS, or luciferase activity to quantitatively measure activity of the signaling pathway.
  • Study NF-κB signaling in 293 TN cells
  • Perform live cell imaging or FACS (300-fold over background NF-κB-dependent GFP signal)
  • Measure pathway activity with luciferase
  • Compatible with a variety of screening methods including small molecule and RNAi
Speed your studies with this pre-built Jurkat cell line for monitoring NF-κB signaling in real time. We’ve already integrated an expression cassette that includes NF-κB-responsive transcriptional elements upstream of a minimal CMV promoter (mCMV)-GFP cassette. Expression of GFP (up to 30-fold over background) only occurs in the presence of active NF-κB signaling, enabling screening for genetic and/or small molecule inhibitors and activators of the NF-κB signaling pathway.
  • Study NF-κB signaling in physiologically-relevant Jurkat cells
  • Use for fluorescence microscopy or FACS
  • Take advantage of the cell line’s 30-fold over background NF-κB-dependent GFP expression
  • Compatible with a variety of screening methods including small molecule and RNAi
Safely study SARS-CoV-2 interactions  Designed to efficiently package most third-generation lentivectors, the pPACK-SPIKE D614G SARS-CoV-2 “S” Pseudotype - D614G Mutant - Lentivector Packaging Mix speeds and simplifies the preparation of lentiviral particles pseudotyped with the SARS-CoV-2 D614G Spike glycoprotein. Based on SBI's highly cited pPACKH1 packaging system but with a truncated SARS-CoV-2 D614G Spike protein [1] replacing the standard VSV-G envelope protein, the pPACK-SPIKE D614G Packaging Mix consists of three plasmids that produce all of the structural and  replication proteins needed to transcribe and package an RNA copy of an expression lentivector into recombinant, D614G “Spike” pseudotyped lentiviral particles. As a result, you can conduct a range of SARS-CoV-2 studies under BSL-2 conditions, including neutralization assays, studies of virus interactions with host surface proteins, and the development of vaccines and therapeutics. For added convenience we also offer pPACK-BALD™, an envelope protein-free lentivector packaging mix that can be used as a negative control for pPACK-SPIKE D614G studies, or for creating lentivirus particles pseudotyped with the envelope protein of your choice. In addition, you can compare the D614G Spike protein to the Spike protein from the original Wuhan-Hu-1 strain with pPACK-SPIKE.
  • Based on SBI’s popular and highly cited pPACKH1 Packaging System
  • Uses codon-optimized SARS-CoV-2 D614G “S” protein in place of VSV-G envelope protein
  • Efficiently incorporates the D614G Spike protein into pseudoviral particles due to a 19 aa C-terminal truncation [1]
  • Ideal for COVID-19 research, such as neutralization assays, under BSL2 conditions
  • Package any 3rd-generation lentivector reporter of your choice, including SBI’s popular LentiLabeler reporters
  • Available as a packaging mix or bundled into a convenient kit that includes PureFection™ Transfection Reagent and PEG-it Virus Precipitation Solution
  • Use with pPACK-BALD™, an envelope protein-free lentivector packaging system that is an ideal negative control
  • Compare to the Spike protein from the original Wuhan-Hu-1 strain when you use pPACK-SPIKE
pPACK-SPIKE D614G SARS-CoV-2 “S” Pseudotype -D614G Mutant - Lentivector Packaging Mix is available as stand-alone packaging mixes with sufficient plasmids for 10 reactions (standard size) or 25 reactions (XL), as well as in a convenient kit format that includes PureFection™ Transfection Reagent and PEG-it Virus Precipitation Solution. See all the available pPACK-SPIKE S protein variants:
Catalog NumberProduct DescriptionSpike protein variant
CVD19-500A-1pPACK-SPIKE SARS-CoV-2 “S” Pseudotype Lentivector Packaging MixOriginal Wuhan-Hu-1 strain
CVD19-590A-1pPACK-SPIKE Alpha (B.1.1.7), SARS-CoV-2 "S" Pseudotype - Alpha (B.1.1.7, UK) Variant - Lentivector Packaging MixΔH69/V70, ΔY144, N501Y, A570D, D614G, P681H, T716I, S982A, D1118H
CVD19-640A-1pPACK-SPIKE Beta (B.1.351), SARS-CoV-2 "S" Pseudotype - Beta (B.1.351) Variant - Lentivector Packaging MixL18F, D80A, D215G, Δ242-244, R246I, K417N, E484K, N501Y, D614G, A701V
CVD19-650A-1pPACK-SPIKE Delta (B.1.617.2), SARS-CoV-2 "S" Pseudotype - Delta (B.1.617.2) Variant - Lentivector Packaging MixT19R, G142D, ΔE156-157, R158G, L452R, T478K, D614G, P681R, D950N
CVD19-630A-1pPACK-SPIKE Gamma (P1), SARS-CoV-2 "S" Pseudotype - Gamma (P1) Variant - Lentivector Packaging MixL18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I, V1176F
CVD19-530A-1pPACK-SPIKE D614G, SARS-CoV-2 “S” Pseudotype – D614G Mutant – Lentivector Packaging MixD614G
CVD19-560A-1pPACK-SPIKE N501Y, SARS-CoV-2 "S" Pseudotype - N501Y Mutant - Lentivector Packaging MixN501Y
CVD19-610A-1pPACK-SPIKE B.1.429, SARS-CoV-2 "S" Pseudotype - B.1.429 (CAL.20C) Variant - Lentivector Packaging MixS13I, W152C, L452R, & D614G
CVD19-620A-1pPACK-SPIKE B.1.525, SARS-CoV-2 "S" Pseudotype - B.1.525 Variant - Lentivector Packaging MixΔH69/V70, Q52R, E484K, D614G, Q677H, & F888L
CVD19-580A-1pPACK-SPIKE B.1.351 RBD Mutations Lentivector Packaging MixK417N, E484K, & N501Y
CVD19-600A-1pPACK-SPIKE B.1.351 S1 Mutations (RBD+D614G) Lentivector Packaging MixK417N, E484K, N501Y, & D614G
LV550A-1pPACK-BALD™ (Negative Control Packaging Mix)An envelope protein-free negative control for pPACK-SPIKE
References
  1. Ou X, et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat. commun. 2020 Mar 27;11(1):1620. doi: 10.1038/s41467-020-15562-9. PMCID: PMC7100515.
Advance your COVID-19 studies with SBI With transfection-ready "N" SARS-CoV-2 Nucleocapsid mRNA, you can go right to studying the native SARS-CoV-2 nucleocapsid protein from the original Wuhan-1 strain. The "N" SARS-CoV-2 Nucleocapsid mRNA delivers robust transient expression to support a range of nucleocapsid protein studies.   See all of our COVID-19-related Expression Options
Catalog NumberProduct name
CVD19-140PA/VA-1ACE2 Expression Lentivector, pCDH-CMV-ACE2-EF1α-Puro (Plasmid or Pre-packaged Lentivirus)
CVD19-100PA/VA-1NRP1 Expression Lentivector, pCDH-CMV-NRP1-EF1α-Neo (Plasmid or Pre-packaged Lentivirus)
CVD19-120PA/VA-1SARS-CoV-2 Nucleocapsid (N protein) Expression Lentivector, pCDH-CMV-SARS-CoV-2-N-EF1α-Puro (Plasmid or Pre-packaged Lentivirus)
CVD19-130PA/VA-1SARS-CoV-2 Spike Glycoprotein (S) Expression Lentivector, pCDH-CMV-SARS-CoV-2-S-EF1α-Puro (Plasmid or Pre-packaged Lentivirus)
CVD19-135PA/VA-1SARS-CoV-2 Humanized Spike Glycoprotein (S) Expression Lentivector, pCDH-CMV-SARS-CoV-2-hS-EF1α-Puro (Plasmid or Pre-packaged Lentivirus)
CVD19-200A-1HEK293 ACE2 Stable Cell Line
CVD19-260A-1HEK293-ACE2-NRP1 Overexpression Stable Cell Line
CVD19-220A-1HEK293 "N" SARS-CoV-2 Nucleocapsid Overexpression Stable Cell Line
CVD19-420A-1
CVD19-425A-1
"N" SARS-CoV-2 Nucleocapsid mRNA
CVD19-430A-1
CVD19-435A-1
"S" SARS-CoV-2 Spike Glycoprotein mRNA
 

How It Works

How It Works

pPACK-SPIKE is easy to use—simply co-transfect the pPACK-SPIKE Plasmids and your lentivector construct into 293TN producer cells or other lentiviral production cells, isolate pseudoviral particles with an optional concentration step, and conduct your studies.

Supporting Data

Supporting Data

See the NF-κB/293/GFP-luc Transcriptional Reporter Cell Line in action

Monitor NF-κB in real time with GFP

Monitor NF-κB in real time with GFP

Quantitate NF-κB Activation with luciferase assaysQuantitate NF-κB Activation with luciferase assays

Resources

Citations

We're sorry, an error has occurred while generating this content.
NF-κB/293/GFP-Luc™ Transcriptional Reporter Cell Line $3,014.00

Products

Catalog Number Description Size Price Quantity Add to Cart
TR860A-1 NF-kB/293/GFP-Luc Transcriptional Reporter Cell Line >2 x 10^6 Cells $3,014.00
- +
Contact Us

Overview

Overview

Monitor NF-κB signaling in Jurkat cells Speed your studies with this pre-built 293 TN-based cell line for monitoring NF-κB signaling in real time. We’ve already integrated an expression cassette that includes NF-κB-responsive transcriptional elements upstream of a minimal CMV promoter (mCMV)-GFP-luciferase cassette. Expression of GFP (up to 300-fold over background) and luciferase only occurs in the presence of active NF-κB signaling, enabling screening for genetic and/or small molecule inhibitors and activators of the NF-κB signaling pathway. Use GFP fluorescence for live cell imaging and FACS, or luciferase activity to quantitatively measure activity of the signaling pathway.
  • Study NF-κB signaling in 293 TN cells
  • Perform live cell imaging or FACS (300-fold over background NF-κB-dependent GFP signal)
  • Measure pathway activity with luciferase
  • Compatible with a variety of screening methods including small molecule and RNAi
Speed your studies with this pre-built Jurkat cell line for monitoring NF-κB signaling in real time. We’ve already integrated an expression cassette that includes NF-κB-responsive transcriptional elements upstream of a minimal CMV promoter (mCMV)-GFP cassette. Expression of GFP (up to 30-fold over background) only occurs in the presence of active NF-κB signaling, enabling screening for genetic and/or small molecule inhibitors and activators of the NF-κB signaling pathway.
  • Study NF-κB signaling in physiologically-relevant Jurkat cells
  • Use for fluorescence microscopy or FACS
  • Take advantage of the cell line’s 30-fold over background NF-κB-dependent GFP expression
  • Compatible with a variety of screening methods including small molecule and RNAi
Safely study SARS-CoV-2 interactions  Designed to efficiently package most third-generation lentivectors, the pPACK-SPIKE D614G SARS-CoV-2 “S” Pseudotype - D614G Mutant - Lentivector Packaging Mix speeds and simplifies the preparation of lentiviral particles pseudotyped with the SARS-CoV-2 D614G Spike glycoprotein. Based on SBI's highly cited pPACKH1 packaging system but with a truncated SARS-CoV-2 D614G Spike protein [1] replacing the standard VSV-G envelope protein, the pPACK-SPIKE D614G Packaging Mix consists of three plasmids that produce all of the structural and  replication proteins needed to transcribe and package an RNA copy of an expression lentivector into recombinant, D614G “Spike” pseudotyped lentiviral particles. As a result, you can conduct a range of SARS-CoV-2 studies under BSL-2 conditions, including neutralization assays, studies of virus interactions with host surface proteins, and the development of vaccines and therapeutics. For added convenience we also offer pPACK-BALD™, an envelope protein-free lentivector packaging mix that can be used as a negative control for pPACK-SPIKE D614G studies, or for creating lentivirus particles pseudotyped with the envelope protein of your choice. In addition, you can compare the D614G Spike protein to the Spike protein from the original Wuhan-Hu-1 strain with pPACK-SPIKE.
  • Based on SBI’s popular and highly cited pPACKH1 Packaging System
  • Uses codon-optimized SARS-CoV-2 D614G “S” protein in place of VSV-G envelope protein
  • Efficiently incorporates the D614G Spike protein into pseudoviral particles due to a 19 aa C-terminal truncation [1]
  • Ideal for COVID-19 research, such as neutralization assays, under BSL2 conditions
  • Package any 3rd-generation lentivector reporter of your choice, including SBI’s popular LentiLabeler reporters
  • Available as a packaging mix or bundled into a convenient kit that includes PureFection™ Transfection Reagent and PEG-it Virus Precipitation Solution
  • Use with pPACK-BALD™, an envelope protein-free lentivector packaging system that is an ideal negative control
  • Compare to the Spike protein from the original Wuhan-Hu-1 strain when you use pPACK-SPIKE
pPACK-SPIKE D614G SARS-CoV-2 “S” Pseudotype -D614G Mutant - Lentivector Packaging Mix is available as stand-alone packaging mixes with sufficient plasmids for 10 reactions (standard size) or 25 reactions (XL), as well as in a convenient kit format that includes PureFection™ Transfection Reagent and PEG-it Virus Precipitation Solution. See all the available pPACK-SPIKE S protein variants:
Catalog NumberProduct DescriptionSpike protein variant
CVD19-500A-1pPACK-SPIKE SARS-CoV-2 “S” Pseudotype Lentivector Packaging MixOriginal Wuhan-Hu-1 strain
CVD19-590A-1pPACK-SPIKE Alpha (B.1.1.7), SARS-CoV-2 "S" Pseudotype - Alpha (B.1.1.7, UK) Variant - Lentivector Packaging MixΔH69/V70, ΔY144, N501Y, A570D, D614G, P681H, T716I, S982A, D1118H
CVD19-640A-1pPACK-SPIKE Beta (B.1.351), SARS-CoV-2 "S" Pseudotype - Beta (B.1.351) Variant - Lentivector Packaging MixL18F, D80A, D215G, Δ242-244, R246I, K417N, E484K, N501Y, D614G, A701V
CVD19-650A-1pPACK-SPIKE Delta (B.1.617.2), SARS-CoV-2 "S" Pseudotype - Delta (B.1.617.2) Variant - Lentivector Packaging MixT19R, G142D, ΔE156-157, R158G, L452R, T478K, D614G, P681R, D950N
CVD19-630A-1pPACK-SPIKE Gamma (P1), SARS-CoV-2 "S" Pseudotype - Gamma (P1) Variant - Lentivector Packaging MixL18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I, V1176F
CVD19-530A-1pPACK-SPIKE D614G, SARS-CoV-2 “S” Pseudotype – D614G Mutant – Lentivector Packaging MixD614G
CVD19-560A-1pPACK-SPIKE N501Y, SARS-CoV-2 "S" Pseudotype - N501Y Mutant - Lentivector Packaging MixN501Y
CVD19-610A-1pPACK-SPIKE B.1.429, SARS-CoV-2 "S" Pseudotype - B.1.429 (CAL.20C) Variant - Lentivector Packaging MixS13I, W152C, L452R, & D614G
CVD19-620A-1pPACK-SPIKE B.1.525, SARS-CoV-2 "S" Pseudotype - B.1.525 Variant - Lentivector Packaging MixΔH69/V70, Q52R, E484K, D614G, Q677H, & F888L
CVD19-580A-1pPACK-SPIKE B.1.351 RBD Mutations Lentivector Packaging MixK417N, E484K, & N501Y
CVD19-600A-1pPACK-SPIKE B.1.351 S1 Mutations (RBD+D614G) Lentivector Packaging MixK417N, E484K, N501Y, & D614G
LV550A-1pPACK-BALD™ (Negative Control Packaging Mix)An envelope protein-free negative control for pPACK-SPIKE
References
  1. Ou X, et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat. commun. 2020 Mar 27;11(1):1620. doi: 10.1038/s41467-020-15562-9. PMCID: PMC7100515.
Advance your COVID-19 studies with SBI With transfection-ready "N" SARS-CoV-2 Nucleocapsid mRNA, you can go right to studying the native SARS-CoV-2 nucleocapsid protein from the original Wuhan-1 strain. The "N" SARS-CoV-2 Nucleocapsid mRNA delivers robust transient expression to support a range of nucleocapsid protein studies.   See all of our COVID-19-related Expression Options
Catalog NumberProduct name
CVD19-140PA/VA-1ACE2 Expression Lentivector, pCDH-CMV-ACE2-EF1α-Puro (Plasmid or Pre-packaged Lentivirus)
CVD19-100PA/VA-1NRP1 Expression Lentivector, pCDH-CMV-NRP1-EF1α-Neo (Plasmid or Pre-packaged Lentivirus)
CVD19-120PA/VA-1SARS-CoV-2 Nucleocapsid (N protein) Expression Lentivector, pCDH-CMV-SARS-CoV-2-N-EF1α-Puro (Plasmid or Pre-packaged Lentivirus)
CVD19-130PA/VA-1SARS-CoV-2 Spike Glycoprotein (S) Expression Lentivector, pCDH-CMV-SARS-CoV-2-S-EF1α-Puro (Plasmid or Pre-packaged Lentivirus)
CVD19-135PA/VA-1SARS-CoV-2 Humanized Spike Glycoprotein (S) Expression Lentivector, pCDH-CMV-SARS-CoV-2-hS-EF1α-Puro (Plasmid or Pre-packaged Lentivirus)
CVD19-200A-1HEK293 ACE2 Stable Cell Line
CVD19-260A-1HEK293-ACE2-NRP1 Overexpression Stable Cell Line
CVD19-220A-1HEK293 "N" SARS-CoV-2 Nucleocapsid Overexpression Stable Cell Line
CVD19-420A-1
CVD19-425A-1
"N" SARS-CoV-2 Nucleocapsid mRNA
CVD19-430A-1
CVD19-435A-1
"S" SARS-CoV-2 Spike Glycoprotein mRNA
 

How It Works

How It Works

pPACK-SPIKE is easy to use—simply co-transfect the pPACK-SPIKE Plasmids and your lentivector construct into 293TN producer cells or other lentiviral production cells, isolate pseudoviral particles with an optional concentration step, and conduct your studies.

Supporting Data

Supporting Data

See the NF-κB/293/GFP-luc Transcriptional Reporter Cell Line in action

Monitor NF-κB in real time with GFP

Monitor NF-κB in real time with GFP

Quantitate NF-κB Activation with luciferase assaysQuantitate NF-κB Activation with luciferase assays

Citations

We're sorry, an error has occurred while generating this content.